These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs. Pok LSL; Shabaruddin FH; Dahlui M; Sockalingam S; Mohamed Said MS; Rosman A; Lau IS; Isa LM; Hussein H; Ng CT; Mahadeva S Int J Rheum Dis; 2018 May; 21(5):943-951. PubMed ID: 29314744 [TBL] [Abstract][Full Text] [Related]
4. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Herings RM; Klungel OH Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213 [TBL] [Abstract][Full Text] [Related]
5. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776 [TBL] [Abstract][Full Text] [Related]
6. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Knill-Jones RP Scand J Rheumatol Suppl; 1992; 96():59-62. PubMed ID: 1439626 [TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490 [TBL] [Abstract][Full Text] [Related]
9. The economic consequences of NSAID-induced gastrointestinal damage. de Pouvourville G; Tasch RF Eur J Rheumatol Inflamm; 1993; 13(1):33-40. PubMed ID: 7821337 [TBL] [Abstract][Full Text] [Related]
10. The economic consequences of NSAID-induced gastropathy: the French context. de Pouvourville G Scand J Rheumatol Suppl; 1992; 96():49-53. PubMed ID: 1439624 [TBL] [Abstract][Full Text] [Related]
11. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Smalley WE; Griffin MR Gastroenterol Clin North Am; 1996 Jun; 25(2):373-96. PubMed ID: 9229579 [TBL] [Abstract][Full Text] [Related]
12. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland. Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD Digestion; 2004; 69(1):10-9. PubMed ID: 14755148 [TBL] [Abstract][Full Text] [Related]
13. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Elliott RA; Hooper L; Payne K; Brown TJ; Roberts C; Symmons D Rheumatology (Oxford); 2006 May; 45(5):606-13. PubMed ID: 16368733 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of the restriction in the use piroxicam in Spain. Maciá Martínez MÁ Reumatol Clin; 2015; 11(6):345-52. PubMed ID: 25636384 [TBL] [Abstract][Full Text] [Related]
15. [Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects]. Lanas A Med Clin (Barc); 2000; 114 Suppl 3():46-53. PubMed ID: 10994564 [TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
17. Economic impact of pharmacists' interventions with nonsteroidal antiinflammatory drugs. Guignard AP; Couray-Targe S; Colin C; Chamba G Ann Pharmacother; 2003 Mar; 37(3):332-8. PubMed ID: 12639158 [TBL] [Abstract][Full Text] [Related]
18. Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece. Liaropoulos L Rheumatology (Oxford); 1999 May; 38 Suppl 1():39-46. PubMed ID: 10369405 [TBL] [Abstract][Full Text] [Related]
19. NSAIDs: a clinical approach to the problems of gastrointestinal side-effects. Butt JH; Barthel JS; Hosokawa MC; Moore RA Aliment Pharmacol Ther; 1988; 2 Suppl 1():121-9. PubMed ID: 2979280 [TBL] [Abstract][Full Text] [Related]
20. The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy. Moore RA Rheumatology (Oxford); 2002 Apr; 41 Supp 1():7-15; discussion 35-42. PubMed ID: 12173280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]